<DOC>
	<DOC>NCT01204112</DOC>
	<brief_summary>The current study is designed to estimate the effect of rifampin (600 mg orally every 24 hours for 7 days) on pharmacokinetics of single 30 mg dose (CP-690,550) in normal healthy volunteers</brief_summary>
	<brief_title>Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy male and/or female subjects (of nonchildbearing potential) Clinically significant disease or condition Recent serious infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Tasocitinib (CP-690</keyword>
	<keyword>550)</keyword>
	<keyword>Rifampin</keyword>
	<keyword>Healthy Volunteers</keyword>
</DOC>